In fiscal 2026, which ended Feb 28, 2026, Medinotec Inc. reported revenue of $9.7 million, up 6.8% from the year before. Net income was $794,502, a profit margin of 8.2%. Operating income came to $1.1 million, an operating margin of 11.2%. Over the twelve months ended Aug 31, 2026, revenue was $10.2 million and net income was $597,032. Across the 4 fiscal years shown, revenue grew from $999,579 in fiscal 2023 to $9.7 million in fiscal 2026, about 113.5% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2027
Aug 31, 2026
|
FY 2026
Feb 28, 2026
|
FY 2025
Feb 28, 2025
|
FY 2024
Feb 29, 2024
|
FY 2023
Feb 28, 2023
|
|---|---|---|---|---|---|
| Revenue |
10
-10.7%
|
10
+6.8%
|
9
+81.5%
|
5
+402.3%
|
1
|
| Cost of revenue |
5
-0.7%
|
5
+7.1%
|
4
+266.6%
|
-3
-517.1%
|
-0
|
| Gross profit |
5
-18.8%
|
5
+6.4%
|
5
+97.3%
|
2
+319.8%
|
1
|
| Research and development |
0
-65.9%
|
0
+64.4%
|
0
+507.7%
|
-0
+65.5%
|
-0
|
| Selling, general and administrative |
4
+54.8%
|
4
+160.1%
|
1
+183.3%
|
-2
-150.1%
|
-1
|
| Operating income |
1
-79.6%
|
1
-65.7%
|
3
+431.4%
|
1
+351.7%
|
-0
|
| Interest income |
—
|
0
-2.7%
|
0
+21.3%
|
0
|
—
|
| Interest expense |
0
-78.5%
|
0
-50.3%
|
0
+163.6%
|
-0
-22.2%
|
-0
|
| Other non-operating income (expense) |
-0
-461.6%
|
-0
-2488.4%
|
0
-91.0%
|
0
-91.6%
|
0
|
| Pretax income |
1
-79.5%
|
1
-64.6%
|
3
+1291.7%
|
-0
+35.2%
|
-0
|
| Income tax |
-0
+33.7%
|
-0
+68.2%
|
-1
-472.9%
|
-0
-132.2%
|
—
|
| Net income |
1
-73.4%
|
1
-63.2%
|
2
+633.6%
|
-0
-14.7%
|
-0
|
| Basic EPS |
—
|
0.07
-61.1%
|
0.18
+700.0%
|
-0.03
+0.0%
|
-0.03
|
| Other measures | |||||
| Depreciation and amortization |
0
+170.3%
|
0
+9.5%
|
0
-16.3%
|
0
+64.7%
|
0
|
| EBITDA |
1
-76.6%
|
1
-64.0%
|
3
+374.1%
|
1
+472.3%
|
-0
|
| Interest coverage |
21.76x
|
12.50x
|
18.09x
|
—
|
—
|
| Margins | |||||
| Gross margin |
49.94%
|
52.71%
|
52.87%
|
48.65%
|
58.21%
|
| Operating margin |
6.58%
|
11.25%
|
35.02%
|
11.96%
|
-23.87%
|
| Pretax margin |
6.45%
|
10.99%
|
33.18%
|
-5.05%
|
-39.16%
|
| Profit margin |
5.85%
|
8.17%
|
23.70%
|
-8.06%
|
-35.29%
|
| EBITDA margin |
7.65%
|
12.08%
|
35.83%
|
13.72%
|
-18.51%
|
| Effective tax rate |
-74.14%
|
-25.69%
|
-28.59%
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- MDNC (OTC)
- Fiscal year ends
- February 28
- Incorporated in
- NV
- Headquarters
- Johannesburg
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1931055
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.